Home Healthcare Healthcare Services In Vivo CRO Market

In Vivo CRO Market Size, Share & Trends Analysis Report By Type (Rodent, Non-Rodent), By Disease Indication (Autoimmune/inflammation conditions, Pain management, Oncology, CNS conditions, Diabetes, Obesity, Others), By GLP Type (Non GLP, GLP Toxicology) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Jay Mehta | Format: | Report Code: SR5227DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. In Vivo CRO Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Rodent
    2. Non-Rodent
  2. In Vivo CRO Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Autoimmune/inflammation conditions
    2. Pain management
    3. Oncology
    4. CNS conditions
    5. Diabetes
    6. Obesity
    7. Others
  3. In Vivo CRO Market, By GLP Type 2022-2034 (USD MILLION/ Units)
    1. Non GLP
    2. GLP Toxicology
  4. Regional In Vivo CRO Market
    1. North America
      1. North America In Vivo CRO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Rodent
        2. Non-Rodent
      2. North America In Vivo CRO Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune/inflammation conditions
        2. Pain management
        3. Oncology
        4. CNS conditions
        5. Diabetes
        6. Obesity
        7. Others
      3. North America In Vivo CRO Market By GLP Type 2022-2034 (USD MILLION/ Units)
        1. Non GLP
        2. GLP Toxicology
      4. U.S.
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      5. Canada
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
    2. Europe
      1. Europe In Vivo CRO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Rodent
        2. Non-Rodent
      2. Europe In Vivo CRO Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune/inflammation conditions
        2. Pain management
        3. Oncology
        4. CNS conditions
        5. Diabetes
        6. Obesity
        7. Others
      3. Europe In Vivo CRO Market By GLP Type 2022-2034 (USD MILLION/ Units)
        1. Non GLP
        2. GLP Toxicology
      4. U.K.
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      5. Germany
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      6. France
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      7. Spain
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      8. Italy
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      9. Russia
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      10. Nordic
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      11. Benelux
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      12. Rest of Europe
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
    3. APAC
      1. APAC In Vivo CRO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Rodent
        2. Non-Rodent
      2. APAC In Vivo CRO Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune/inflammation conditions
        2. Pain management
        3. Oncology
        4. CNS conditions
        5. Diabetes
        6. Obesity
        7. Others
      3. APAC In Vivo CRO Market By GLP Type 2022-2034 (USD MILLION/ Units)
        1. Non GLP
        2. GLP Toxicology
      4. China
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      5. Korea
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      6. Japan
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      7. India
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      8. Australia
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      9. Singapore
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      10. Taiwan
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      11. South East Asia
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      12. Rest of Asia-Pacific
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
    4. Middle East and Africa
      1. Middle East and Africa In Vivo CRO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Rodent
        2. Non-Rodent
      2. Middle East and Africa In Vivo CRO Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune/inflammation conditions
        2. Pain management
        3. Oncology
        4. CNS conditions
        5. Diabetes
        6. Obesity
        7. Others
      3. Middle East and Africa In Vivo CRO Market By GLP Type 2022-2034 (USD MILLION/ Units)
        1. Non GLP
        2. GLP Toxicology
      4. UAE
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      5. Turkey
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      6. Saudi Arabia
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      7. South Africa
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      8. Egypt
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      9. Nigeria
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      10. Rest of MEA
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
    5. LATAM
      1. LATAM In Vivo CRO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Rodent
        2. Non-Rodent
      2. LATAM In Vivo CRO Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Autoimmune/inflammation conditions
        2. Pain management
        3. Oncology
        4. CNS conditions
        5. Diabetes
        6. Obesity
        7. Others
      3. LATAM In Vivo CRO Market By GLP Type 2022-2034 (USD MILLION/ Units)
        1. Non GLP
        2. GLP Toxicology
      4. Brazil
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      5. Mexico
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      6. Argentina
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      7. Chile
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      8. Colombia
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
      9. Rest of LATAM
        1. Rodent
        2. Non-Rodent
        3. Autoimmune/inflammation conditions
        4. Pain management
        5. Oncology
        6. CNS conditions
        7. Diabetes
        8. Obesity
        9. Others
        10. Non GLP
        11. GLP Toxicology
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.